Wakamoto Pharmaceutical Co.,Ltd.

Tokyo Stock Exchange 4512.T

Wakamoto Pharmaceutical Co.,Ltd. Free Cash Flow Yield on January 29, 2025: -8.99%

Wakamoto Pharmaceutical Co.,Ltd. Free Cash Flow Yield is -8.99% on January 29, 2025, a -242.73% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Wakamoto Pharmaceutical Co.,Ltd. 52-week high Free Cash Flow Yield is 6.82% on March 05, 2024, which is 175.89% above the current Free Cash Flow Yield.
Wakamoto Pharmaceutical Co.,Ltd. 52-week low Free Cash Flow Yield is -9.31% on January 14, 2025, which is -3.57% below the current Free Cash Flow Yield.
Wakamoto Pharmaceutical Co.,Ltd. average Free Cash Flow Yield for the last 52 weeks is -5.58%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Tokyo Stock Exchange: 4512.T

Wakamoto Pharmaceutical Co.,Ltd.

CEO	Mr. Arata Igarashi
IPO Date	Jan. 1, 2001
Location	Japan
Headquarters	2-2-2, Nihonbashi Honcho
Employees	403
Sector	Health Care
Industries Pharmaceuticals

Description

Wakamoto Pharmaceutical Co., Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong Wakamoto, a gastrointestinal drug for digestion, intestinal regulation, and nutritional supplementation. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943. Wakamoto Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years